NCT02041260 2021-10-15
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Thomas Jefferson University
Phase 2 Unknown
Thomas Jefferson University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano